Today: 29 April 2026
Browse Category

NASDAQ:MDLN 9 December 2025 - 18 December 2025

Medline Stock (MDLN) After the Bell: IPO Closes, Shares Ease to $39.49 — What to Know Before Market Open Dec. 19, 2025

Medline Stock (MDLN) After the Bell: IPO Closes, Shares Ease to $39.49 — What to Know Before Market Open Dec. 19, 2025

Medline Inc. closed its upsized IPO on Dec. 18, selling 248.4 million shares at $29 each, including the full underwriters’ option, raising about $7.2 billion. Shares ended regular trading at $39.98, down 2.49%, and traded near $39.49 after hours. The stock remains well above its IPO price after debuting at $41 on Wednesday. Proceeds will be used to repay debt and buy out pre-IPO owners.
18 December 2025
··
Medline Inc. Class A Common Stock MDLN Stock News and Forecast: Shares Surge After 2025’s Biggest IPO as Debt and Tariff Risks Take Center Stage

Medline Inc. Class A Common Stock MDLN Stock News and Forecast: Shares Surge After 2025’s Biggest IPO as Debt and Tariff Risks Take Center Stage

Medline Inc. shares opened at $35 on their Nasdaq debut December 17, 2025, after a $29 IPO price, closing at $41 for a 41% first-day gain. The stock pulled back to $39.73 in early pre-market trading December 18. The IPO valued Medline at roughly $55.4 billion at the close. The offering was expected to close December 18, with most proceeds earmarked to repay debt from its 2021 buyout.
18 December 2025
·
Medline IPO 2025: Inside the $5.37 Billion Nasdaq Listing and One of Private Equity’s Biggest Exits

Medline IPO 2025: Inside the $5.37 Billion Nasdaq Listing and One of Private Equity’s Biggest Exits

Medline Inc. has set terms for a U.S. IPO aiming to raise up to $5.37 billion, valuing the company at as much as $55.3 billion. The Illinois-based medical-supply firm plans to sell 179 million shares on Nasdaq under the ticker MDLN at $26–$30 each, with pricing expected around December 16. Private-equity backers Blackstone, Carlyle, and Hellman & Friedman are selling down, while the Mills family remains the largest shareholder.
9 December 2025
·

Stock Market Today

  • Nasdaq Futures Rise Ahead of Fed Decision and Major Tech Earnings
    April 29, 2026, 9:10 AM EDT. Nasdaq futures gained 0.4% ahead of the Federal Reserve's policy decision and earnings reports from tech giants Alphabet, Microsoft, Amazon, and Meta. Markets are cautious following a broad sell-off in major indices driven by chip stock weakness linked to slowing growth at AI firm OpenAI. Investors await the Fed's stance on inflation and interest rates, with crude oil prices rising amid unresolved US-Iran tensions. The Fed is expected to hold rates steady in Jerome Powell's final meeting before his replacement, Kevin Warsh, awaits Senate approval. Key focus remains on AI capital expenditure and the potential for further rate hikes in 2024. Earnings from AbbVie, AstraZeneca, Total Energies, UBS, and GSK are also in focus.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop